Tatiana Topchiy

Tatiana Topchiy

Auto-generated profile, based on publicly available information

Tatiana Topchiy

Central State Medical Academy of the President of the Russian Federation

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MAMaria D. Ardatskaya
Maria D. Ardatskaya
LBLudmila I. Butorova
Ludmila I. Butorova
MKMarina A. Kalashnikova
Marina A. Kalashnikova
NNNelli R. Nugaeva
Nelli R. Nugaeva
YOYury V. Ovchinnikov
Yury V. Ovchinnikov
ТБТопчий Татьяна Борисовна
Топчий Татьяна Борисовна
Background. The novel coronavirus infection COVID-19 can be manifested by damage to the organs of the gastrointestinal tract (GIT). Damage to the gastrointestinal tract by the SARS-CoV-2 virus leads to a violation of the microbial-tissue complex of the mucous membrane of the digestive tract. A common gastroenterological manifestation of COVID-19 is diarrhea. Aim. Study of the clinical features of gastroenterological disorders and the possibility of optimizing the treatment of diarrheal syndrome in patients with COVID-19 with a mild form of viral infection. Materials and methods. The observation group consisted of 230 patients with mild COVID-19: K-group (n=115) with respiratory symptoms, I group (n=115) with gastrointestinal manifestations in combination and without signs of respiratory damage. In order to compare the effectiveness of treatment of diarrheal syndrome, patients of group I are randomized into 2 subgroups: Ia (n=58) prebiotic treatment (Zacofalk) and Ib (n=57) enterosorbents. Results. The development of gastrointestinal symptoms with SARS-CoV-2 infection is significantly more often noted in comorbid patients (67%). Gastrointestinal symptoms were dominated by diarrhea (93.9%) and flatulence (76.5%), in 1/3 of patients they were the first manifestos of infection. It was established that in 98.4% of patients of group I (against 42.6% of the K-group) signs of infectious intoxication were detected. In patients with gastrointestinal lesions, an elongation of the febrile period by 91.5 days was noted, a later (6 days) verification of the viral etiology of the disease. It was found that in patients of group I, the regression of clinical symptoms, the duration of viral disease, the dynamics of antibody formation, the prognosis for the development of IBS-like disorders in the post-infectious period depended on the treatment. In patients taking (Zacofalk), these indicators were significantly better. Conclusion. In mild cases, to reduce the severity of viral intestinal damage, for effective relief of intestinal symptoms, to reduce the risk of IBS-like symptoms, it is advisable to prescribe (Zacofalk) in an initial dose of 3 tablets per day.

19 April 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
LBL. I. Butorova
L. I. Butorova
MAM. D. Ardatskaya
M. D. Ardatskaya
MOMikhail A. Osadchuk
Mikhail A. Osadchuk
NKN. G. Kadnikova
N. G. Kadnikova
ELE. I. Lukianova
E. I. Lukianova
ТМТуаева Елена Михайловна
Туаева Елена Михайловна
Low patient compliance due to the development of adverse events in the form of antibiotic-associated diarrhea (AAD) is considered as the main reason for the failure of the eradication of optimized anti-Helicobacter therapy regimens. A key mechanism for the development of AAD is to reduce the number and species diversity of bacteria that form butyric acid. Aim. The purpose of this study was to study the comparative effect on the clinical effectiveness of eradication therapy (ET) of Helicobacter pylori infection and metabolic changes in the colon microbiota of additional inclusion in the optimized treatment regimen of the combined prebiotic Zakofalk (inulin + butyrate) with probiotics (lacto- and bifidobacteria in an amount of at least 1017 СFU). Materials and methods. 120 patients with chronic gastroduodenal diseases and infected H. pylori were еxamined. A comparative analysis of the effect of a combined prebiotic and lacto-bifid-containing probiotics on improving the effectiveness of the optimized ET scheme and improving its tolerability, as well as on the quantitative and qualitative content of short-chain fatty acids (SFA) in feces. The success of eradication was controlled by a 13C urease breath test. Results. According to the results of the study in randomized groups of patients, an excellent percentage of eradication (95%) was achieved in patients who performed ET with the addition of the prebiotic Zakofalk. In the same group of patients, there was an increase in the absolute content of SFA and a significant increase in the concentration of butyric acid. In the group of patients who received ET with the addition of probiotics, an acceptable level of eradication was achieved (85.7%), but no changes in SFA were found indicating an increase in the number or activity of the butyrate-producing flora. Patients who performed ET without the addition of pre-probiotics did not achieve the target percentage of successful eradication (83.3%), and a significant quantitative decrease in SFA was found with a significant decrease in the proportion of butyric acid. Conclusion. The inclusion of Zakofalk in the ET scheme, in comparison with probiotics, significantly increases the probability of successful eradication, more effectively restores the metabolic potential of the microbiota, and prevents the development of AAD.

3 September 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
LBL. I. Butorova
L. I. Butorova
MAM. D. Ardatskaya
M. D. Ardatskaya
MOMikhail A. Osadchuk
Mikhail A. Osadchuk
ADA. E. Drobysheva
A. E. Drobysheva
EZE. A. Zagrebina
E. A. Zagrebina
ТМТуаева Елена Михайловна
Туаева Елена Михайловна
In the clinical classification of cholelithiasis, biliary sludge (BS) is distinguished as the pre-stone stage. Ursodeoxycholic acid (UDCA) is a drug with an evidence base for effective and safe effects on BS. The therapeutic equivalence of various UDCA drugs remains an important issue for clinical practice. Aim. To conduct a comparative analysis of the effectiveness of the use of UDCA: Ursofalk with other UDCA drugs for the treatment of BS in a fixed dose of 10 mg/kg of body weight. Material and methods. The observation group consisted of 225 patients with various types of BS. In randomized groups, the comparison of the effectiveness of UDCA drugs in the dissolution of BS was determined by the data of ultrasound of the gallbladder. Dynamic ultrasound cholecystography using a standardized technique was performed to study the effect of the compared drugs on the contractile function of the liver. When analyzing the impact of ursotherapy on the clinical manifestations of BS, the dynamics of biliary pain syndrome and dyspeptic disorders were evaluated. Results. A comparative analysis of the effectiveness of UDCA drugs for BS lysis with a high degree of confidence established the advantage of Ursofalk: after 3 months in 80%, and after 6 months of therapy in 95.65% of patients, a regression of BS was detected. In the group of patients who took other UDCA, the corresponding indicators were 46.36% and 67.27%. The greatest effectiveness of ursotherapy was demonstrated in the BS variant by the type of suspension of hyperechogenic particles, the lowest in the variant by the type of putty-like bile in the form of mobile or fixed clots. In the last variant of BS, the relationship between the success of lysis with the extension of the UDCA intake period to 6 months and the preferred choice of Ursofalk was traced. Normalization of the contractile function of the gallbladder was noted in patients who took Ursofalk. Conclusion. From the standpoint of therapeutic effectiveness, the drug of choice for the treatment of BS, regardless of its type, is Ursofalk, which has proven the best dynamics of BS litolysis, recovery of the contractile function of the gastrointestinal tract, and relief of clinical symptoms.

15 February 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
EVE A Volchkova
E A Volchkova
KLK S Legkova
K S Legkova
TTT B Topchy
T B Topchy
Over the past two years, the entire medical community has taken up the fight against the new coronavirus infection. At the initial encounter with COVID-19, it seemed that this virus mainly affects the respiratory system. Still, with long-term observation, it turned out that the consequences of this disease can be much more severe and associated with lung damage and thromboembolic complications, and be a trigger for autoimmune diseases. According to the literature, after suffering COVID-19, some patients debuted systemic lupus erythematosus, hemolytic anemia, thrombocytopenia, developed GuillainBarr syndrome, vasculitis, and multiple sclerosis, and a case of autoimmune hepatitis (AIH) was described in foreign literature. AIH is a fairly rare disease, the prevalence of which in Europe is 1618 cases per 100 thousand inhabitants, affecting mainly women. It is known that chemicals and drugs (minocycline, diclofenac, methyldopa, infliximab, etanercept), viruses (HAV, HEV, EBV, HCV, CMV), environmental factors can serve as triggers of the autoimmune process in the liver. This article presents two clinical cases of AIH that developed after suffering a new coronavirus infection, which we consider as the initial provoking factor of autoimmune inflammation. Given the rarity of AIH, the description of new triggers is of clinical interest. It may be useful for doctors of different specialties since they faced drug-induced liver damage against the background of antiviral and immunobiological therapy. In the domestic literature, there have not yet been any publications devoted to the debut of AIH in adults after coronavirus infection.

12 August 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
TTTatiana В. Topchiy
Tatiana В. Topchiy
MAMaria D. Ardatskaya
Maria D. Ardatskaya
LBLudmila I. Butorova
Ludmila I. Butorova
LМLeonid V. Маslovskii
Leonid V. Маslovskii
ОМОleg N. Мinushkin
Оleg N. Мinushkin
АДАрдатская Мария Дмитриевна
Ардатская Мария Дмитриевна
COVID-19 infection may present with gastrointestinal lesions in up to 25% of patients. One of the target organs of the SARS-CoV-2 virus is the intestine. The pathogenesis of intestinal damage in a new coronavirus infection remains unclear and requires further in-depth study. Possible mechanisms include a direct cytotoxic effect of the virus, a persistent reduction in butyrate-producing bacteria, side effects of drugs, Clostridioides difficile infection, microvascular thrombosis, and the immune-mediated inflammatory reactions in the intestine. The most common symptom of intestinal damage during coronavirus infection, both in the acute phase and in the post-COVID period, is diarrhea. The impact of many aggressive factors on the intestines can form both long-term functional disorders and be the cause of the onset of organic diseases. Treatment should be aimed at possible causes of intestinal damage (Clostridioides difficile), as well as reducing inflammation, restoring intestinal permeability, cytoprotection of mucosal cells, replenishing butyric acid deficiency. When choosing a therapy for intestinal disorders, preference should be given to drugs with a pleiotropic effect in order to influence various possible pathogenetic mechanisms.

22 October 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
OMO. N. Minushkin
O. N. Minushkin
LML. V. Maslovskiy
L. V. Maslovskiy
MBM. I. Bulanova
M. I. Bulanova
EGE. S. Gordienko
E. S. Gordienko
TTT. B. Topchiy
T. B. Topchiy
NBN. I. Beylina
N. I. Beylina
Введение. Функциональные заболевания кишечника (ФЗК) занимают одно из ведущих мест среди патологии кишечника. В настоящее время научные данные свидетельствуют о недостаточной эффективности существующих методов лечения ФЗК и о необходимости проведения дальнейших испытаний. Настоящее исследование посвящено оценке влияния лечения препаратами СТИМ Лакс и СТИМ на клинические проявления у больных ФЗ и ФД. Цель исследования. Оценка эффективности биологически активных добавок (БАД) СТИМ и СТИМ Лакс у 39 больных с функциональными расстройствами кишечника. Задачи исследования. Оценка влияния препарата на клинические симптомы по данным индивидуального дневника и с помощью специализированных опросников с балльной оценкой симптомов до и после курса лечения. Материалы исследования. В исследование принято 39 больных, разделенных на две группы. Из них 20 больных ФЗ (4 мужчины и 16 женщин; средний возраст – 40,3 ± 8,9 лет): проводилась монотерапия препаратом СТИМ Лакс (1 таблетка 3 раза в день в течение 30 дней) – и 19 больных ФД (10 мужчин и 9 женщин; средний возраст – 36,9 ± 14,1 лет): проводилась терапия препаратом СТИМ (2 таблетки 3 раза в день в течение 30 дней). До и после курса лечения проводили карболеновую пробу, клинически оценивали частоту и характер стула, выраженность метеоризма, урчания, переливания, боли в животе. Результаты. Терапия ФЗ и ФД препаратами СТИМ и СТИМ Лакс эффективно уменьшает частоту и интенсивность клинических симптомов, нормализует время транзита по карболеновой пробе, частоту стула. Усиление метеоризма наблюдали у 7 (17,9%) больных, к его разрешению в течение 1–3 дней приводило уменьшение дозы препарата, не влияя на конечный результат. Выводы. Настоящее исследование свидетельствует о высокой эффективности и хорошей переносимости лечения препаратами СТИМ Лакс и СТИМ больных ФЗК.